7a9u

From Proteopedia
Revision as of 15:59, 16 December 2020 by OCA (talk | contribs)
Jump to navigation Jump to search

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamideN-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(3-methyl-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propanamide

Structural highlights

7a9u is a 1 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:,
Gene:BRD4, HUNK1 (HUMAN)
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Disease

[BRD4_HUMAN] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.[1] [2]

Function

[BRD4_HUMAN] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).

Publication Abstract from PubMed

Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease-modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment-screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment-protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.

A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands.,Grant EK, Fallon DJ, Hann MM, Fantom KGM, Quinn C, Zappacosta F, Annan RS, Chung CW, Bamborough P, Dixon DP, Stacey P, House D, Patel VK, Tomkinson NCO, Bush JT Angew Chem Int Ed Engl. 2020 Aug 3. doi: 10.1002/anie.202008361. PMID:32745361[3]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

  1. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003 Jan 15;63(2):304-7. PMID:12543779
  2. French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, Vargas SO, Perez-Atayde AR, Fletcher JA. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am J Pathol. 2001 Dec;159(6):1987-92. PMID:11733348 doi:10.1016/S0002-9440(10)63049-0
  3. Grant EK, Fallon DJ, Hann MM, Fantom KGM, Quinn C, Zappacosta F, Annan RS, Chung CW, Bamborough P, Dixon DP, Stacey P, House D, Patel VK, Tomkinson NCO, Bush JT. A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands. Angew Chem Int Ed Engl. 2020 Aug 3. doi: 10.1002/anie.202008361. PMID:32745361 doi:http://dx.doi.org/10.1002/anie.202008361

7a9u, resolution 1.44Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA